Qualifying Biomarkers to Support Rare Disease Regulatory Pathways
Case example: Heparan sulfate in neuronopathic lysosomal storage diseases

Public Workshop: In-Person and Virtual
February 21, 2024 | 10am-4pm (eastern)

Advancing Psychedelic Clinical Study Design
Virtual Public Meeting
Day 1: January 31, 2024 | 10am-2pm (eastern)

Integrating Clinical Studies Into Health Care Delivery:
Post-Market Evidence Generation for Medical Products
Virtual Public Meeting
November 14, 2023 | 3:30-5pm (Eastern)

How can FDA and other stakeholders better facilitate and support post-market pragmatic evidence generation studies – studies that answer clinically meaningful questions and address gaps in clinical evidence that directly impact how care is managed in the United States?

Front-of-Package Nutrition Labeling
Virtual Public Meeting
November 16, 2023 | 2:30-5pm (Eastern)

On November 16 we convened a Front-of-Package Nutrition Labeling virtual public meeting that included opportunity for stakeholder comment.

Strategies for Improving Public Understanding of FDA-Regulated Products

Virtual Public Meeting

Mitigating Risks from Human Xylazine Exposure

Public Meeting: In-person and Virtual 
October 4, 2023 | 9:15 am-5 pm (eastern)

The Foundation partnered with the Food and Drug Administration (FDA) to host "Mitigating Risks from Human Xylazine Exposure," a day-long meeting with both in-person and virtual attendance. 

On September 12 and 13, the Foundation, in collaboration with the U.S. Food and Drug Administration, hosted a webinar to explore Good Clinical Practice Considerations for Trials with Pragmatic or Decentralized Features. We convened international experts in the conduct of clinical trials with pragmatic or decentralized features.